top of page

Levin, RF., Bisaga, A., Sullivan, AM., Williams, RA., Cates-wessel, K. (2016) 'A review of a national training initiative to increase provider use of MAT to address the opioid epidemic ', Am J Addict. 2016 Dec;25(8):603-609.

Am J Addict. 2016 Dec;25(8):603-609.

A review of a national training initiative to increase provider use of MAT to address the opioid epidemic

Frances R Levin , Adam Bisaga, Maria A Sullivan, Arthur Robin Williams, Kathryn Cates-Wessel 


Background and objectives: The Providers' Clinical Support System for Medication Assisted Treatment (PCSS-MAT) initiative focuses on training and mentoring health professionals in the treatment of opioid use disorders (OUD) using pharmacological strategies. Led by the American Academy of Addiction Psychiatry (AAAP), PCSS-MAT is a consortium representing four of the five national professional organizations authorized by DATA 2,000-AAAP, American Osteopathic Academy of Addiction Medicine, American Psychiatric Association, and American Society of Addiction Medicine. DATA organizations are authorized to train physicians to prescribe buprenorphine for OUD treatment. The primary aim of PCSS-MAT is to substantially increase evidence-based practices with medications for OUD.

Methods: This review describes the development of PCSS-MAT, an ongoing national initiative funded by the Substance Abuse and Mental Health Services Administration (SAMHSA), to address the training needs posed by this critical public health problem. Core initiatives include: (1) Training and mentoring activities for primary care physicians; (2) Outreach to multidisciplinary professional organizations, (3) Creating a resource portal for families, patients, and communities for OUD treatment.

Results: Educational outreach to providers addresses the needs of patients with OUD and common co-occurring psychiatric and medical disorders.

Discussion and conclusions: The overall scope of PCSS-MAT is to increase access to evidence-based treatment of substance use disorders as a public health priority. Recently enacted legislation requires office-based opioid treatment programs to offer all Food and Drug Administration-approved (FDA) forms of MAT.

Article reference

bottom of page